Company AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 16:35:08 17/06/2024 BST 5-day change 1st Jan Change
12,428 GBX -0.66% Intraday chart for AstraZeneca PLC -1.37% +17.25%

Business Summary

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

Sales per Business

GBP in Million2022Weight2023Weight Delta
Oncology
37.4 %
11,878 33.0 % 13,793 37.4 % +16.12%
Cardiovascular, Renal and Metabolism
23.1 %
7,459 20.7 % 8,515 23.1 % +14.16%
Rare Disease
16.9 %
5,726 15.9 % 6,246 16.9 % +9.08%
Respiratory and Immunology
13.3 %
4,680 13.0 % 4,913 13.3 % +4.97%
Alliance
3.1 %
- - 1,149 3.1 % -
Other Medicines
2.6 %
1,319 3.7 % 946 2.6 % -28.29%
Vaccines and Immune Therapies
2.2 %
3,845 10.7 % 814 2.2 % -78.83%
Collaboration
1.3 %
1,098 3.1 % 478 1.3 % -56.50%

Sales per region

GBP in Million2022Weight2023Weight Delta
United States
39.6 %
14,027 39.0 % 14,578 39.6 % +3.93%
China
12.8 %
4,662 12.9 % 4,724 12.8 % +1.32%
Japan
7.9 %
3,236 9.0 % 2,928 7.9 % -9.51%
United Kingdom
7.4 %
2,530 7.0 % 2,709 7.4 % +7.07%
Other Rest of Europe
6.8 %
2,197 6.1 % 2,502 6.8 % +13.89%
Germany
4.6 %
1,544 4.3 % 1,689 4.6 % +9.36%
Other Asia, Africa and Australasia
4.5 %
1,953 5.4 % 1,645 4.5 % -15.77%
Sweden
3.7 %
1,397 3.9 % 1,371 3.7 % -1.89%
Other Americas
3.7 %
954 2.6 % 1,354 3.7 % +41.94%
France
2.5 %
899 2.5 % 927 2.5 % +3.12%
Canada
2.1 %
947 2.6 % 778 2.1 % -17.82%
Spain
1.8 %
599 1.7 % 681 1.8 % +13.73%
Italy
1.8 %
597 1.7 % 654 1.8 % +9.61%
Australia
0.9 %
464 1.3 % 314 0.9 % -32.32%

Managers

Managers TitleAgeSince
Chief Executive Officer 64 30/09/12
Director of Finance/CFO 50 31/07/21
Chief Tech/Sci/R&D Officer - 31/07/23
Chief Tech/Sci/R&D Officer 60 -
Chief Tech/Sci/R&D Officer 56 31/12/19
Compliance Officer - 31/12/94
Chief Tech/Sci/R&D Officer - 17/05/23
Chief Operating Officer 53 31/05/15
Corporate Officer/Principal - 31/12/00
General Counsel - 29/02/16

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 30/09/17
Director/Board Member 63 26/04/17
Director/Board Member 68 31/03/99
Corporate Officer/Principal 71 31/05/13
Director/Board Member 67 31/07/21
Chairman 67 31/08/19
Chief Executive Officer 64 30/09/12
Director/Board Member 64 30/11/17
Director of Finance/CFO 50 31/07/21
Director/Board Member 63 31/12/18

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,550,256,302 1,498,113,319 ( 96.64 %) 0 96.64 %

Shareholders

NameEquities%Valuation
BlackRock Investment Management (UK) Ltd.
4.420 %
68,512,693 4.420 % 10 633 M p
Wellington Management Co. LLP
4.201 %
65,120,892 4.201 % 10 107 M p
The Vanguard Group, Inc.
3.614 %
56,033,000 3.614 % 8 696 M p
Investor AB (Investment Company)
3.328 %
51,587,810 3.328 % 8 007 M p
Norges Bank Investment Management
2.216 %
34,358,000 2.216 % 5 332 M p
BlackRock Fund Advisors
1.925 %
29,840,869 1.925 % 4 631 M p
Legal & General Investment Management Ltd.
0.9874 %
15,307,263 0.9874 % 2 376 M p
SSgA Funds Management, Inc.
0.9819 %
15,222,000 0.9819 % 2 363 M p
BlackRock Advisors LLC
0.9735 %
15,091,905 0.9735 % 2 342 M p
Fidelity Management & Research Co. LLC
0.9504 %
14,733,459 0.9504 % 2 287 M p
NameEquities%Valuation
T. Rowe Price International Ltd.
1.976 %
61,271,974 1.976 % 4 780 M p
Wellington Management Co. LLP
1.584 %
49,121,861 1.584 % 3 832 M p
PRIMECAP Management Co.
1.385 %
42,945,175 1.385 % 3 351 M p
Capital Research & Management Co. (International Investors)
1.113 %
34,521,875 1.113 % 2 693 M p
Fidelity Management & Research Co. LLC
0.6678 %
20,704,467 0.6678 % 1 615 M p
Jennison Associates LLC
0.5572 %
17,276,282 0.5572 % 1 348 M p
Fiduciary Trust Company International
0.5555 %
17,222,116 0.5555 % 1 344 M p
Eaton Vance Management
0.4871 %
15,101,147 0.4871 % 1 178 M p
Sanders Capital LLC
0.4780 %
14,818,983 0.4780 % 1 156 M p
The Ayco Co. LP
0.3982 %
12,346,115 0.3982 % 963 M p
NameEquities%Valuation
Caixa DTVM SA
0.002994 %
278,553 0.002994 % 4 M p

Holdings

NameEquities%Valuation
18,750,000 75.00% 1,384,260,375 $
35,043,624 9.89% 940,965,109 $
108,923,023 37.58% 593,182,802 $
71,065,878 16.76% 63,879,696 $
16,000,000 22.30% 41,860,800 $
7,485,500 9.26% 20,559,450 $
44,803 3.39% 454,750 $
884,956 1.99% 54,867 $

Company contact information

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk
address AstraZeneca PLC(AZN)

Group companies

NameCategory and Sector
Insurance Brokers/Services
Miscellaneous Commercial Services
Alexion Pharmaceuticals, Inc. /New/
Financial Conglomerates
Pharmaceuticals: Major
Financial Conglomerates
Astrazeneca Holdings BV
Astrazeneca Treasury BV
Miscellaneous Commercial Services

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7 USD
Average target price
174.4 USD
Spread / Average Target
+10.62%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Company AstraZeneca PLC
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW